{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:37:23Z","timestamp":1786977443383,"version":"build-2736575974"},"reference-count":28,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>BNC210 is an investigational small molecule selective negative allosteric modulator of the alpha\u20107 nicotinic acetylcholine receptor (\u03b17 nAChR). It is an anxiolytic compound with a novel mechanism of action. In a series of Phase 1 clinical trials in healthy volunteers, psychometric test batteries showed that BNC210 did not cause attention, cognition, or memory impairment, negative effects on mood or emotional stability, sedation, or addiction, ruling out undesirable side effects of known anxiolytic compounds. In healthy volunteers, target engagement at the \u03b17\u00a0nAChR was demonstrated in a nicotine shift assay using quantitative electroencephalography, and BNC210 demonstrated improvement in panic\u2010like symptoms in a cholecystokinin tetrapeptide panic model. Initial clinical trials used an aqueous suspension formulation of BNC210 to cover a wide dosage range; however, its pharmacokinetic parameters were consistent with solubility\u2010limited absorption and a significant food effect. A dispersible tablet formulation was then developed with improved bioavailability and is being used in Phases 2 and 3 clinical trials. Collectively, the Phase 1 data demonstrated desired properties of BNC210 supporting proof\u2010of\u2010concept clinical trials. BNC210 is currently being developed for acute, as\u2010needed treatment of social anxiety disorder and chronic treatment of post\u2010traumatic stress disorder.<\/jats:p>","DOI":"10.1002\/cpdd.1609","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T09:28:04Z","timestamp":1758965284000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Pathway to Proof\u2010of\u2010Concept for BNC210, a Negative Allosteric Modulator of the Alpha\u20107 Nicotinic Acetylcholine Receptor (nAChR), for Treatment of Psychiatric Disease"],"prefix":"10.1002","volume":"15","author":[{"given":"Paul","family":"Rolan","sequence":"first","affiliation":[{"name":"Clinical Pharmacology Consulting and University of Adelaide Medical School  Adelaide Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Doolin","sequence":"additional","affiliation":[{"name":"Clinical Neuphoria Therapeutics Inc. Adelaide Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharam","family":"Paul","sequence":"additional","affiliation":[{"name":"Clinical Neuphoria Therapeutics Inc. Adelaide Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Crossman","sequence":"additional","affiliation":[{"name":"Clinical Neuphoria Therapeutics Inc. Adelaide Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Odontiadis","sequence":"additional","affiliation":[{"name":"Clinical Neuphoria Therapeutics Inc. Adelaide Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Danjou","sequence":"additional","affiliation":[{"name":"Principal Danjou Consulting Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Smith","sequence":"additional","affiliation":[{"name":"Medical Neuphoria Therapeutics Inc. Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyros","family":"Papapetropoulos","sequence":"additional","affiliation":[{"name":"Medical Neuphoria Therapeutics Inc. Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,9,27]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2015.316"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2014.12.028"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2024.109836"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2023.2192922"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2019.12.013"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-01141-5"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2025.116387"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2400380"},{"key":"e_1_2_10_10_1","unstructured":"O'ConnorS DoolinE NetterbergI KarlsonM RolanP.The therapeutic potential of BNC210 for the treatment of PTSD is informed by pharmacometrics analysis.Poster T255 presented at the Society of Biological Psychiatry Annual Meeting; May 16 2019;Chicago IL."},{"key":"e_1_2_10_11_1","unstructured":"Food and Drug Administration.Guidance for Industry Food\u2010Effect Bioavailability and Fed Bioequivalence Studies US Food and Drug Administration;2002"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1974.tb02285.x"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2004.02279.x"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00735818"},{"key":"e_1_2_10_15_1","volume-title":"A Manual for the Wechsler Adult Intelligence Scale","author":"Wechsler D","year":"1955"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.3109\/00207459008994241"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1991.122"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2296719"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2354.1999.00180.x"},{"issue":"6","key":"e_1_2_10_20_1","first-page":"385","article-title":"Topographic brain mapping of EEG in neuropsychopharmacology\u2013Part II. Clinical applications (pharmaco EEG imaging)","volume":"9","author":"Saletu B","year":"1987","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1971122part1245"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12632"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/hbm.20522"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1991.01810310021005"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/026988119300700303"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1993.tb04156.x"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00174511"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1986.90"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1994.tb04232.x"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1609","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpdd.1609","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1609","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T11:39:23Z","timestamp":1772969963000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.1609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,27]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1002\/cpdd.1609"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.1609","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,27]]},"assertion":[{"value":"2025-07-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e1609"}}